Please assess the completion status of the following clinical trial:

Trial Title: Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Metastatic Renal Cell Carcinoma.~2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.~Exclusion Criteria:~1. Prior chemotherapy.~2. Prior treatment with lenalidomide, thalidomide, pomalidomide, or sunitinib.~3. Laboratory values outside normal ranges.~4. Myocardial infarction (MI) within past 12 months.~5. Current congestive heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle
- Cohorts F and G (Type: EXPERIMENTAL): Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).